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Lithium has been used for decades to treat Bipolar Disorder. Some of its therapeutic
benefits may be through inhibition of Glycogen Synthase Kinase (GSK)-3. Enhanced
GSK3 activity associates with development of Alzheimer’s disease (AD), therefore
lithium is a currently used therapeutic with potential to be repurposed for prevention
of Dementia. An important step toward a clinical trial for AD prevention using lithium is
to establish the dose of lithium that blocks GSK3 in Mild Cognitive Impairment (MCI),
a high-risk condition for progression to AD. We investigated volunteer recruitment,
retention, and tolerance in this population, and assessed biomarkers of GSK3 in MCI
compared to control and after lithium treatment. Recruitment was close to target, with
higher than anticipated interest. Drop out was not related to lithium blood concentration.
Indeed, 33% of the withdrawals were in the first week of very low dose lithium. Most
made it through to the highest dose of lithium with no adverse events. We analyzed
18 potential biomarkers of GSK3 biology in rat PBMCs, but only four of these gave a
robust reproducible baseline signal. The only biomarker that was modified by acute
lithium injection in the rat was the inhibitory phosphorylation of Ser9 of GSK3beta
(enhanced in PBMCs) and this associated with reduced activity of GSK3beta. In contrast
to the rat PBMC preparations the protein quality of the human PBMC preparations was
extremely variable. There was no difference between GSK3 biomarkers in MCI and
control PBMC preparations and no significant effect of chronic lithium on the robust
GSK3 biomarkers, indicating that the dose reached may not be sufficient to modify
these markers. In summary, the high interest from the MCI population, and the lack of
any adverse events, suggest that it would be relatively straightforward and safe to recruit
to a larger clinical trial within this dosing regimen. However, it is clear that we will need
an improved PBMC isolation process along with more robust, sensitive, and validated
biomarkers of GSK3 function, in order to use GSK3 pathway regulation in human PBMC
preparations as a biomarker of GSK3 inhibitor efficacy, within a clinical trial setting.
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INTRODUCTION
The pharmacological treatment of Dementia is limited to the
treatment of symptoms, primarily due to the ever increasing
number of failed clinical trials (Hardy, 2009; Wang et al., 2016;
Amanatkar et al., 2017), while the paucity of non-amyloid
targeting drugs in development is highly concerning (Cummings
et al., 2017). In contrast, there is increasing awareness of the
importance of identifying high risk groups and developing
Dementia prevention strategies.
Mild Cognitive impairment (MCI) can be thought of as a
prodromal phase of Dementia with a significant proportion
of MCI patients converting to Dementia. Interventions in
MCI may provide the best opportunities to delay or prevent
the development of irreversible pathology and debilitating
symptoms (Petersen et al., 2001). In order to generate novel
therapeutics as rapidly as possible one approach is to investigate
the “repositioning” of therapeutics currently used for other
neurological conditions, with acceptable safety and side effect
profiles, that have mechanistic potential to target the molecular
pathways in brain associated with early AD development (e.g.,
amyloid, tangle, inflammation, etc.) (Corbett et al., 2012).
Glycogen Synthase Kinase-3 (GSK3) influences many
important cellular processes (Jope and Johnson, 2004; Kockeritz
et al., 2006; Sutherland, 2011), and its dysregulation has been
linked to the pathophysiology of numerous age-related diseases
including Alzheimer’s disease (AD) and inflammation (Cohen
and Goedert, 2004; O’Brien and Klein, 2007; Hooper et al., 2008;
Sutherland, 2011; Gao et al., 2012; Beurel et al., 2013; Russo
et al., 2013). Importantly, partial deletion (pharmacological
or genetic) of GSK3 reduces the severity of disease in many
preclinical models, including models of familial AD (Jope et al.,
2007; Hooper et al., 2008; Sutherland, 2011; Avrahami et al.,
2013; Ly et al., 2013). Furthermore, transgenic overexpression of
GSK3, specifically in mouse brain, promotes AD-like symptoms
and generates pathology (Lucas et al., 2001). Importantly, GSK3
activation is directly linked to the development of cognitive
impairment independent of AD pathology (King et al., 2013).
This implies that GSK3 inhibition could have clinical benefits
from early stage development right through to late stage disease.
However, the wide spectrum of important biological actions
influenced by GSK3 activity has questioned the clinical safety of
a global GSK3 inhibition approach, especially as genetic ablation
of GSK3 has serious health implications including disruption of
brain development and repair (Jiang et al., 2005; Kim et al., 2009).
However, GSK3 in human dementia is related to abnormally
high GSK3 activity in adults, and no GSK3 inhibitor toxicology
studies have been reported in an adult preclinical model with
excessive GSK3 activity.
The safety concerns around GSK3 inhibition are doubly
surprising since a GSK3 inhibitor is in everyday clinical use
without the side-effects observed in some animal models of
GSK3 ablation. Lithium is a well characterized (if non-selective)
inhibitor of GSK3 (Klein and Melton, 1996; O’Brien and Klein,
2007, 2009; Can et al., 2014) with a well-known and acceptable
side effect profile. Indeed, it has been used effectively for decades
in the treatment of mood disorder, and although the precise
mechanisms of action remain the subject of some debate there
is evidence for at least some of its neuroprotective actions
being mediated by inhibition of GSK3 (O’Brien and Klein, 2007,
2009; Malhi et al., 2013; Can et al., 2014). Importantly, patients
prescribed long term lithium for Bipolar disorder have lower
incidence of all forms of dementia compared to short term use
or alternative therapies (Sutherland and Duthie, 2015). This is
tantalizing evidence that lithium, or other GSK3 inhibitors, have
the potential to prevent conversion to dementia.
Lithium is generally well tolerated as a long-term therapy for
Bipolar disease in humans. However, toxicity can lead to ataxia
and confusion, and in severe cases it can be life threatening.
For this reason, lithium serum levels are routinely monitored in
clinical practice and kept within a narrow therapeutic range of
0.4–0.75 mM/l (McKnight et al., 2012). Clinical studies giving
lithium to elderly people with AD (at doses relevant to treatment
of Bipolar disease) had relatively few side effects (Macdonald
et al., 2008; Hampel et al., 2009). A study with lithium in
people with MCI reported excellent volunteer retention and
tolerability up to 1 year of lithium administration (Forlenza
et al., 2011a). This treatment indicated a trend toward cognitive
benefit and 91% tolerability but was too short to include
effects on conversion to Dementia (Forlenza et al., 2011a).
It seems reasonable therefore to suggest that lithium is a
clinically viable GSK3 inhibitor that is available for immediate
use in trials to evaluate GSK3 inhibition as an anti-dementia
therapeutic agent.
The therapeutic range of lithium contains the IC50 (50%
inhibition constant) for direct GSK3 inhibition in vitro [approx.
0.5 mM (Davies et al., 2000)], suggesting that pharmacologically
relevant GSK3 inhibition would be achieved by the doses
used to treat Bipolar disease. However, lithium regulates GSK3
activity by several distinct mechanisms (Sutherland and Duthie,
2015), which may mean that inhibition of GSK3 in patients
will occur with even lower levels of lithium than predicted
from in vitro obtained IC50 values. Therefore, experimentally
evaluating the lithium concentration required to inhibit GSK3
in relevant human populations becomes a valuable exercise prior
to balancing safety concerns with therapeutic benefits. However,
measuring changes in GSK3 activity in humans is challenging,
and almost impossible in intact brain.
The studies where lithium administration to rodent models
of dementia has beneficial actions on brain imaging, behavior,
or AD pathology [for example (O’Brien et al., 2004; Noble
et al., 2005; Zhang et al., 2011; Sudduth et al., 2012; Yu et al.,
2012; Chen et al., 2013; de Cristobal et al., 2014)] measure the
N-terminal inhibitory phosphorylation status of GSK3 in a tissue
lysate to assess GSK3 activity status. However, this modification
does not inhibit GSK3 against all of its downstream targets
(Frame et al., 2001), and thus is not sufficient to provide a
comprehensive assessment of GSK3 activity. In reality, GSK3
inhibition may occur at lithium concentrations lower than those
required to regulate this phosphorylation or to competitively
inhibit GSK3 activity, and specific targets may be regulated
by different mechanisms of GSK3 regulation (Robertson et al.,
2018). There is evidence that therapeutic doses of lithium
are sufficient to increase GSK3 N-terminal phosphorylation in
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TABLE 1 | Potential molecular biomarkers of GSK3 activity, classified by the
relationship to GSK3 function.
(1) GSK3 regulatory modifications Effect of modification
Ser9 (GSK3b)/Ser21 (GSK3a)
phosphorylation




Required for GSK3 kinase activity
Thr390 (GSK3b only) Inhibits GSK3b activity
(2) Downstream targets (effect of
phosphorylation)
Residues phosphorylated by GSK3
Glycogen Synthase (inhibited) Ser641/645/649/653 (inhibits)
b-catenin (degraded) Ser33/37 (degradation-so total
b-catenin also a potential marker)
CRMP2 (cell location change) Thr509/514/518
CRMP4 (cell location change) Thr509/514/518
Tau (unknown but disease associated) Ser231 Ser396 or PHF1(multiple)
(3) Upstream regulatory pathways Sites that monitor pathway
PI-3K-PKB (main pathway for GSK3
inhibition through Ser9/21)
Thr308 and Ser473 PKB (active)
mTOR-S6K (has ability to inhibit GSK3
at Ser9/21)
Ribosomal S6 protein Ser240/244
(active)
RAS-MAPkinase (has ability to inhibit
GSK3 at Ser9/21)
Thr180-Tyr182 p42/44 MAPK (active)
PKA (has ability to inhibit GSK3 at
Ser9/21)
VASP (PKA target)
P38MAPK (inhibits GSK3b at Thr390) ATF2 or Thr180-Tyr182 p38 MAPK
(active)




human blood cells in Bipolar disorder (Li et al., 2007) or MCI
(Forlenza et al., 2011b).
Alternative “potential biomarkers” of GSK3 activity status are
detailed in Table 1. There are several phosphorylation sites on
GSK3 that influence GSK3 activity, including Tyr 279/216 and
Thr390 (GSK3β only) (Table 1), and total GSK3 isoform mRNA
or protein can also vary in some disease states. One can also
monitor the signaling pathways that regulate phosphorylation
of these sites, such as the PI3K-Akt pathway (Cross et al.,
1995). Activation of these pathways may be extrapolated to
an assumption of inhibition of GSK3 (Table 1). Possibly more
informative is quantitative assessment of phosphorylation of
direct downstream targets of GSK3 (Table 1; Sutherland, 2011).
However, this depends on antibody availability and protein
detection in the tissues of interest.
The current study aimed to assess and validate many of
the potential biomarkers for GSK3 activity in Table 1, in
rodent Peripheral Blood Mononuclear cells (PBMCs). We then
took robust biomarkers from that study to generate pilot
information on inhibition of GSK3 by lithium in people with
MCI. Importantly we also aimed to extend the evidence that
recruiting and retaining this population to a trial which involved
taking lithium, a drug not normally prescribed to MCI, was
achievable. We performed three studies, one where we gave
rats an acute dose of lithium and measured GSK3 biomarkers
in PBMCs, hippocampus and cortex, one (Arm 1) where we
compared GSK3 biomarkers in PBMCs between volunteers with
MCI and age-matched controls, and one (Arm 2) where we
performed a step-wise increasing lithium dosing experiment in
MCI volunteers over 12 weeks.
MATERIALS AND METHODS
Materials
Vacutainers for blood collection were purchased from BD
(Wokingham, United Kingdom) (367869), Optiprep media
(D1556), lithium chloride (203637), and sodium chloride
(S7653) were from Sigma (Gillingham, United Kingdom),
Mono-Poly resolving media from MP Biomedicals (Santa
Ana, United States) (0916980). Protease inhibitor tablets
were from Roche (11836170001) and Bradford protein assay
reagent was from Biorad (Watford, United Kingdom) (500-
0006). The nitrocellulose (Amersham Protran) membrane
and Phosphocellulose P81 paper were from GE Healthcare
Life Sciences (Little Chalfort, United Kingdom) (10600002),
the Enhanced Chemiluminescence (ECL) Kit used was from
Amersham (RPN2209) and CL-Xposure film from Thermo
Scientific (Waltham, United States). The radioisotope, γ-32P-
ATP was purchased from Perkin Elmer (Waltham, United States).
All other chemicals were of the highest grade available. All
antibodies used in this study are detailed in Table 2.
Animals
All experiments were performed using male Wistar rats (Harlan
Ltd., United Kingdom), initial body weight 150–175 g. Animals
were housed in cages of four (12:12 h light: dark cycle) at an
ambient temperature of 22 ± 1◦C and 50% humidity, with
ad libitum access to food and water. All animal procedures
were approved by the University of Dundee Ethical Review
Process and were performed in accordance with UK Home
Office regulations (under the auspices of Project License
PIL60/4280). Animals were assigned at random to one of three
treatment groups (i) Control (Saline), (ii) Low dose lithium
chloride (2 nmoles/kg i.p.), or (iii) High dose lithium chloride
(4 nmoles/kg i.p.). 3 h post injection animals were sacrificed
by cervical dislocation and blood samples collected by cardiac
puncture for the preparation of PBMCs and plasma lithium
analysis. Brain regions (hippocampus, hypothalamus, cortex, and
cerebellum) and liver samples were isolated and snap frozen in
liquid nitrogen for subsequent biochemical analysis.
Rodent Lithium Assessment
One milliliter of whole rat blood was collected from each
animal on Sodium Heparin. Samples were spun and serum
transferred to 1.5 ml Eppendorf tubes prior to running on
an AVL 9180 Electrolyte Analyser, alongside an appropriate
lithium standard curve.
Rodent PBMC Collection
Peripheral Blood Mononuclear cells were collected from the
rat blood samples immediately after collection using OptiPrep
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TABLE 2 | Antibodies used in this work.
Dilution Secondary
Antibody Manufacturer Cat no (1% BSA in TBST) (in TBST)
Anti-Actin Sigma A3853 1:5000 Mouse
Anti-β-Catenin Cell Signaling 2698 1:1000 Mouse
Anti-phospho-β-Catenin Cell Signaling 9561 1:1000 Rabbit
Anti-c-Myc Abcam AB32 1:1000 Mouse
Anti-phospho-CRMP2 (Ser509/514) In house 1:1000 Sheep
Anti-phospho-CRMP2 (Ser522) In house 1:1000 Sheep
Anti-total CRMP2 Cell Signaling 9393 1:1000 Rabbit
Anti-phospho-CRMP4 (Ser509) In house 1:1000 Sheep
Anti-total Glycogen synthase Cell Signaling 3886 1:1000 Rabbit
Anti-phospho-Glycogen synthase Cell Signaling 3891 1:1000 Rabbit
Anti-GSK3 α/β(for IB) Cell Signaling 5676 1:1000 Rabbit
Anti-phospho GSK3 α/β (S21/9) Cell Signaling 8566 1:1000 Rabbit
Anti-GSK3α (for IP) Abcam Ab40870 1 µg/0.1mg of lysate Rabbit
Anti-GSK3β (for IP) In House 1 µg/0.1mg of lysate Sheep
Anti-total ERK (p44/42 MapK) Cell Signaling 9102 1:1000 Rabbit
Anti-phospho-ERK (Thr202/Tyr204) Cell Signaling 9101 1:1000 Rabbit
Anti-total PKB Cell Signaling 2920 1:1000 Mouse
Anti-phospho-PKB (Thr308) Cell Signaling 9275 1:1000 Rabbit
Anti-phospho-PKB (Ser473) Cell Signaling 9271 1:1000 Rabbit
Anti-S6 Cell Signaling 2217 1:1000 Rabbit
Anti-phospho-S6 (Ser240/244) Cell Signaling 2215 1:1000 Rabbit
Anti-Tau5 Millipore MAB361 1:1000 Mouse
Anti-phospho-Tau (Thr231) Millipore AB9668 1:1000 Rabbit
Anti-phospho-Tau (Ser396) Cell Signaling 9632 1:1000 Mouse
VASP In house 1:1000 Sheep
HRP conjugated anti-RABBIT IgG Thermo Fisher S1440 1:2500 N/A
Anti-RABBIT IgG (H&L) IRDye800 R©Conjugated Rockland 613-132-122 1:10000 N/A
Anti-RABBIT IgG (H&L) IRDye800 R©Conjugated Licor 925-32211 1:5000 N/A
Anti-SHEEP IgG (H&L) IRDye800 R©Conjugated Rockland 613-431-002 1:10000 N/A
Anti-MOUSE IgG (H+L) Alexa Fluor 680 Life Technologies A21057 1:5000 N/A
density gradient medium using the flotation technique as per
manufacturer’s instructions. Protein was harvested from the
cell pellet in lysis buffer [25 mM Tris–HCl (pH 7.4), 50 mM
NaF, 0.1 M NaCl, 1 mM EDTA, 5 mM EGTA, 1% Triton-X,
10 mM Na-pyrophsphate, 0.1% beta-mercaptoethanol, 1 mM Na-
vanadate, protease inhibitor cocktail tablet (Roche 11836170001)
and 0.27M sucrose] and snap frozen in liquid N2 prior to
storage at−80◦C.
Study Design
There were two arms to the human study, firstly a comparison
of GSK3 biomarkers in PBMCs between volunteers with MCI
and age-matched controls. This included a comparison of the
biomarkers from the same individual in two samples taken
12 weeks apart. Secondly, an intervention arm, where volunteers
with MCI were given lithium tablets for 9 weeks, with a step wise
increase from 100 to 200 mg/d then 400 mg/d for 3 weeks each,
followed by a 3 week wash out period (Figure 1). Blood was taken
at baseline, 1 and 3 weeks after lithium dose change as detailed
in Figure 1. The study was approved by the North of Scotland
Research Ethics committee, number16/NS/006.
Volunteer Recruitment and Definition
of MCI
Participants over age 55 and with a diagnosis of MCI were
recruited from Tayside Old Age Psychiatry and Geriatric
Medicine outpatient clinics and by using Join Dementia
Research (JDR) Database. Of 830 clinic contacts screened via
consultant caseloads, 67 MCI patients were identified and
invited by letter plus 4 contacts identified through existing local
research lists and 3 via JDR. MCI was defined according to
Petersen’s criteria (Petersen et al., 2001). Two brief standardized
questionnaires [Bristol Activities of Daily Living Schedule and
Geriatric Depression Scale Short Form (15 point version)]
were administered to check diagnosis and existing cognitive
assessments were documented from case file. The control group
was recruited via two routes, firstly through Join Dementia
Research and secondly by approaching spouses/partners/relatives
of similar age to the MCI group but who lack an MCI
diagnosis. Exclusions for the Study Arm 1 group were as
follows; Dementia, Diabetes, current medication of Lithium or
NSAIDS, BMI < 18 or > 30, incapacity to consent, Rheumatoid
Arthritis and Autoimmune Inflammatory disorders and for Study
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 June 2019 | Volume 12 | Article 163
fnmol-12-00163 June 27, 2019 Time: 15:16 # 5
Duthie et al. Lithium Regulation of GSK3 in Humans
FIGURE 1 | Lithium intervention Study Design (Arm 2). Eleven volunteers were
given low dose (100 mg daily) for 3 weeks, then medium dose (200 mg daily)
for 3 weeks, high dose (400 mg daily) for 3 weeks, prior to a 3 week washout
period. Blood samples were taken for safety measures, PBMC preparation
and Lithium measure at baseline (visit 1), 1 and 3 weeks after starting each
dose (visit 2–7), and after washout (visit 8).
Arm 2 the following additional exclusion criteria were applied:
contraindication to Lithium Carbonate (Priadel) according to
Summary of Product Characteristics, Moderate renal failure
(defined by eGFR < 60 mL/min/1.73 m2) or severe Renal
failure (defined by eGFR < 29 mL/min/1.73 m2), epilepsy, and
suicidality. Screening included baseline blood tests for renal
function and thyroid function.
Safety assessments were face to face and occurred at each
scheduled visit at weeks 1, 3, 4, 6, 7, 9, and 12. Participants were
asked about general health and the presence of any common
side effects and a Lithium side effects rating scale (LISERS)
completed where any side effects were reported. The blister
pack was examined for compliance. Blood lithium concentration
and renal function were assessed as standard clinical safety
measures in line with guidelines for routine clinical practice.
Lithium > 0.7 mmMol/L or significant deterioration in renal
function (defined by eGFR falling to < 60 mL/min/1.73 m2) or
acute kidney injury [diagnosed by acute rise in creatinine blood
result according to NICE Guidelines for Acute Kidney Injury
(Levin et al., 2008)] would result in withdrawal from lithium and
entry to washout.
Human PBMC Collection
Volunteer blood (13–18 ml) was collected in Na-heparin
containing vacuettes, kept at room temperature and processed
within 6 h of collection. In sterile test tubes 3.5 ml of blood
was carefully layered on top of 3 ml Mono-poly resolving media.
These were centrifuged for 45 min, 800 × g in a swinging bucket
rotor at room temperature without brake (Beckman Coulter
Allegra X-12 centrifuge). The plasma layer at the top of the tube
was then removed and discarded using a Pasteur’s pipette and
the top layer of cells containing the mononuclear leucocytes was
collected and combined in a clean test tube. The cell suspension
was washed with three volumes of PBS and centrifuged 10 min,
at room temperature, 250 × g with brake on. The cell pellet was
washed in PBS and centrifuged again. An equal volume of PBS
was added to the pellet, the cells were resuspended gently and the
cell mixture transferred to a cryovial and snap frozen in liquid N2
prior to storage at−80◦C.
Cell Lysis and Western Blot Analysis
The PBMC pellets were lysed on ice in lysis buffer. Following
centrifugation to remove insoluble material, supernatants were
collected and protein concentrations were determined using the
Bradford method. Lysates were made up to equal concentrations
with lithium dodecyl sulfate sample buffer added and subjected
to SDS-polyacrylamide gel electrophoresis on 4–12% NuPAGE
polyacrylamide gels (Novex, Life Technologies), then either
stained using Coomassie Blue (SimplyBlueTMSafe Stain,
Invitrogen, CA, United States), or transferred to nitrocellulose
membrane. Membranes were blocked in 5% (w/v) BSA,
incubated with primary antibodies overnight at 4◦C, and then
Alexa-fluor secondary antibodies for 1 h at room temperature.
Proteins were visualized using the Licor Odyssey. When probing
for phospho Akt(Ser473), HRP secondary antibody was used,
detection achieved with ECL and proteins visualized on film
using different exposure times, typically between 10 s and 10 min.
Quantification of Immunoblots
Protein bands were quantified using the Image Studio software
(Licor). Odyssey images were quantified directly while ECL
images on film were scanned using a desktop scanner and
imported into the software. The background was determined
around each box individually, either left and right, top and
bottom, or both with varying width, dependent upon the layout
of each blot, but kept consistent per blot. Normalization was done
by generating a ratio against a loading control (usually actin), or
for Phosphorylation sites a ratio against the total protein signal
of the protein of study where antibodies were available. The
differences between groups were determined by using a Student t
test. Analyses were performed using Excel (Microsoft Corp.).
Sequential Immunoprecipitation
and Assay of GSK3 Isoforms
A total of 200 µl of (50:50) Protein A agarose beads in PBS
were conjugated to 20 µg of either anti-GSK3β or anti-GSK3α by
incubating for 1 h at room temperature with shaking. Unbound
antibody was removed by washing with lysis buffer and 5µl of the
(50:50) anti-GSK3β-beads incubated with 100 µl of 1 µg/µl cell
lysate overnight at 4◦C with shaking. GSK3β immunocomplexes
were isolated by centrifugation at 3000× g for 5 min. Supernatant
was incubated with 5 µl of (50:50) anti-GSK3α-beads for 4 h
at 4◦C prior to isolation of the GSK3α immunocomplexes by
centrifugation at 3000 × g for 5 min. All immunocomplexes
were washed with 1 ml of lysis buffer, followed by 1 ml of
kinase assay buffer (25 mM TRIS, 0.1 mM EDTA, 5% glycerol)
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containing 0.5 M NaCl and then 1 ml of kinase assay buffer before
resuspending to 10 µl in assay buffer.
Each washed immunocomplex was incubated with PGS2
peptide (10 µM final), MgCl2 (10 mM final), γ − 32P-ATP
(0.1 mM final, 0.5 × 106 CPM/nmole) in assay buffer in a
final volume of 50 µl at 30◦C for 20 min. The assay was
stopped by spotting the assay mix onto P81 phosphocellulose
paper and placing in 10 mM Phosphoric Acid (PA). Papers were
washed 4× 5 min in PA then once in acetone and air dried.
Phosphate incorporation into the GSK3 substrate was quantified
by counting the paper in a scintillation counter. One unit of
activity of each protein kinase was calculated as the amount
required to transfer 1 nmole of phosphate/min. The differences
between groups were determined by using a Student t test.
Analyses were performed using Excel (Microsoft Corp.).
RESULTS
Clinical Studies
Recruitment of Volunteers With a Diagnosis of Mild
Cognitive Impairment (for Study Arms 1 and 2)
The recruitment strategy is provided in Figure 2. Study Arm 1
contained six MCI and eleven controls (all providing two blood
samples, 12 weeks apart), and Study Arm 2 recruited eleven
MCI volunteers for lithium treatment (eight blood samples across
12 weeks). The number of participants excluded due to BMI
above 30 was greater than anticipated from this age group and
was the most common reason for exclusion.
Retainment and Safety
There were no retainment issues in Study Arm 1, with no
withdrawals and no adverse events reported. In contrast, of
the eleven participants in Arm 2, six withdrew from the
lithium titration phase (54%) due to reported side effects
(n = 4), non-compliance (n = 1) and altered blood results
(n = 1). All participants completed a lithium wash out visit
(>3 weeks after last lithium dose). Interestingly, there was no
association between lithium blood concentration and withdrawal
(withdrawals had plasma lithium in the range 0.2–0.61 mmol/L,
mean 0.38 mmol/L, while non-withdrawals plasma lithium
ranged from 0.33–0.54 mmol/L, mean 0.42 mmol/L). The mean
duration of lithium titration before withdrawal was 5 weeks
(note; high dose lithium only started in week 6). Table 3
provides the plasma lithium of all participants through the study
period, including those that withdrew. Five of the volunteers
provided the full set of seven blood samples for lithium
measure (Table 3).
There were no serious adverse events reported. Six parti-
cipants experienced side effects (54%) with two of these
continuing with the lithium titration phase to completion.
Side effects reported at either moderate or severe intensity
included: fatigue, metallic taste, dry mouth, nausea, decreased
concentration, insomnia, or confusion. Feeling drowsy or
lethargic during the day was the most commonly reported side
effect with five of the six participants reporting this in either mild,
moderate or severe intensity.
Only one individual of the eleven given lithium exhibited a
change in renal function (mild reduction in eGFR to 57 mls/min
with accompanying mild increase in creatinine). Examination of
the case files revealed that while normal at trial initiation, this
individual had previously had similar mild impairment of renal
function on blood testing. There were no instances of electrolyte
disturbance or other renal problems during the trial.
Biomarker Studies
GSK3 Biomarkers in Rodent PBMC and Association
With Neuronal GSK3 Activity
Our initial study was to investigate whether the GSK3 biomarkers
in Table 1 could be detected in a PBMC preparation from
rats, and whether detectable markers respond to lithium
administration. Additionally, we wanted to try to investigate
whether any lithium induced biomarker responses in the PBMCs
associated with changes in the brain. Ultimately, we wanted to
generate a focussed, validated, panel of GSK3 biomarkers as
a readout for GSK3 function in humans to investigate early
dementia, and for establishing efficacy of lithium dose.
However, we could detect only eight of the biomarkers
from Table 1 in rat PBMCs either using immunoblotting,
loading up to 50 µg of total protein on the gels, or by
immunoprecipitation of GSK3 isoforms from cell lysates and
assay (Figure 3A, for examples of immunoblots, and Table 4 for
IP assay data). Importantly, only four of these biomarkers were
detected robustly (signal > twice background), and reproducibly
from multiple separate PBMC preparations (Table 5). These were
Phospho-Ser21/9 of GSK3, total GSK3 (both by immunoblot,
Figure 3A), and GSK3α and GSK3β activity (measured by
IP-assay, Table 4). We are confident that the blotting reagents
were suitable for detection of each protein (positive controls
included in Figure 3A and biomarkers were detectable in
brain tissues, Figure 3). Therefore, the major GSK3 regulatory
pathways and the best characterized GSK3 substrates to date all
proved difficult to detect robustly in PBMCs by immunoblotting.
We next investigated whether any of these markers were
influenced by a single i.p. injection of LiCl vs. NaCl (control).
3 h after injection the blood lithium levels in the rats were
raised in a dose dependent fashion, with roughly twice the
plasma lithium concentration achieved by doubling the lithium
dose (Table 6). Cell based studies had previously suggested that
0.5–1 mM Lithium is required to acutely reduce cellular GSK3
activity by around 50%, and we were achieving these levels in
the rat blood with a single injection. Therefore, we monitored
the potential GSK3 biomarkers in protein lysates isolated from
PBMCs (Figure 3A) and two brain regions (Figures 3B,C), in
order to assess the response to Lithium injection (summary
in Table 5). In addition, we immunoprecipitated, and assayed
the specific activity of the two GSK3 isoforms from the same
tissues (Table 4), as lithium is reported to enhance covalent
inhibitory modification of GSK3. The phosphorylation of Ser9
of GSK3β was enhanced in PBMCs by lithium injection (see
insert table in Figure 3A for quantification of immunoblots), and
consistent with this, the activity of GSK3β (but not GSK3α) was
significantly reduced in PBMCs (Tables 4, 5). This indicates that
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FIGURE 2 | Consort diagram detailing the recruitment process for the clinical studies.
TABLE 3 | Plasma lithium level (mmoles/l) during stepwise increase in lithium dose in volunteers.
Patient ID
Visit 20 29 19 24 15 14 16 10 30 32 21
Low dose 2 (week 1) <0.2 <0.2 <0.2 ? <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2
3 (week 3) <0.2 <0.2 <0.2 ? <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2
Medium dose 4 (week 4) <0.2 0.3 w w <0.2 <0.2 0.24 <0.2 <0.2 0.23 0.4
5 (week 6) 0.23 0.33 w w <0.2 <0.2 0.3 <0.2 <0.2 0.45 <0.2
High dose 6 (week 7) <0.2 0.61 w w 0.39 0.4 0.37 0.36 0.33 w <0.2
7 (week 9) w 0.44 w w 0.38 0.33 0.54 0.36 0.47 w w
8 (week 12) <0.2 NA <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 <0.2
The 11 participants in Study Arm 2 had plasma lithium levels measured at baseline (visit 1) then after 1 and 3 weeks of each lithium dose, and once at least 3 weeks
after stopping lithium (washout). Two volunteers withdrew (w) while on low dose (19 and 24), two on medium dose (21 and 32), and one did not take lithium as
asked (volunteer 20). Low dose did not generate detectable lithium levels (0.2 assay detection limit), medium dose raised plasma lithium in four out of eight volunteers
to detectable levels, with 0.45 mmoles/l the highest reported level at this dose (32). Finally, high dose raised plasma levels in every volunteer remaining in the study
(29,15,14,16,10, and 30), with an average of 0.415 mmoles/l and a range of 0.33–0.61. All lithium levels returned to baseline within 3 weeks of discontinuation. Bold
values indicate the completion of the study.
Frontiers in Molecular Neuroscience | www.frontiersin.org 7 June 2019 | Volume 12 | Article 163
fnmol-12-00163 June 27, 2019 Time: 15:16 # 8
Duthie et al. Lithium Regulation of GSK3 in Humans
a plasma lithium level of 0.83 mM was sufficient to enhance Ser9
phosphorylation and at least partly inhibit GSK3β activity, and
could be achieved by this single lithium injection. Interestingly,
double the plasma level of lithium (1.6 mM) did not further
increase the degree of Ser9 phosphorylation nor enhance the
inhibition of GSK3β, suggesting the effect had plateaued. In
addition, this plasma level of lithium did not significantly
alter any of the measurable GSK3 biomarkers studied in the
hippocampus, or cortex (Figures 3B,C, quantified in table within
Figure 3A). This may mean the brain does not get exposed to the
same level of lithium as the blood, or the time point we examined
was not optimal for effects on the brain.
GSK3 Biomarkers in Human PBMCs
The next step in our study examined the GSK3 biomarkers,
identified in the rat study, in PBMCs isolated from human
volunteers. In Study Arm 1 we wanted: (1) to establish that
the GSK3 activity biomarkers detectable in rat PBMCs could
also be detected in cells isolated from the human population of
greatest interest (i.e., MCI), (2) to investigate the reproducibility
of marker detection in two PBMC preparations generated from
the same individual but taken 12 weeks apart, and finally, (3) to
ask whether there were major differences in any of these markers
that associated with MCI diagnosis. We recruited six patients
with MCI (mean age 78, range 77–81) and eleven non-MCI, age-
matched controls (mean age 76, range 65–84) to this arm. In
addition, we had baseline samples from the 11 MCI volunteers
recruited to Arm 2 below (making n = 17 for the MCI group).
A major finding of this work was that the consistency
of protein recovery and quality between the human PBMC
preparations, even those generated from samples obtained from
the same individual, was varied (Figure 4A for protein stains). In
some cases, total protein recovery was relatively low (e.g., visit 1
volunteer X6), in others there was clear evidence of substantial
degradation (e.g., visit 2 volunteer 03, visit 1 volunteer 04, visits 1
and 2 volunteer X3, visit 2 volunteer 09). The Coomassie stained
gels emphasized that 13 of the 45 PBMC isolates investigated had
noticeable overall protein degradation. Nevertheless, we went on
to examine several of the biomarkers from Table 1, in particular
the four which were robustly detected in rat PBMCs. There
was also variability in the biomarkers across the samples, even
between samples from the same individuals, mostly associated
with protein quality (Figure 4B), however, we were able to
confirm which biomarkers could be detected in human PBMCs.
In addition to phosphorylation of Ser9/21 of GSK3, total GSK3
and the activity of the GSK3 isoforms, we could also detect
the GSK3 substrate c-myc (Figure 4B). Due to the poor quality
of protein isolation we quantified the protein staining in every
sample (22 healthy and 12 MCI in Study arm 1, plus the baseline
PBMC preparations from the 11 MCI volunteers in Study Arm 2
below, so n = 22 and 23, respectively), and discarded any samples
with less than 20% of the average protein level by protein staining
(Figure 4A, e.g., visit 1 volunteer X6), or samples with < 10% of
the average actin staining (Figure 4B, e.g., visit 2 Volunteer 03).
We then quantified the immunoblot densities for the remaining
samples (control group n = 14, MCI group n = 18), for every
detectable biomarker. The phosphorylation of GSK3β at Ser-9
(47 kDa) and the activity of GSK3b were the only biomarkers that
were significantly affected by lithium in the rat study (Figure 3A).
In the human PBMCs we generated a P-GSK3β to actin ratio for
every sample. The healthy control samples had a P-GSK3β:actin
ratio of 0.0283 ± 0.018 (n = 14) and the MCI samples had a
ratio of 0.0295 ratio ± 0.015 (n = 18). These data sets were
FIGURE 3 | Continued
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FIGURE 3 | Biomarkers of GSK3 in rat tissues following lithium injection. Rats were given an i.p. injection of vehicle or lithium chloride as detailed in section
“Materials and Methods,” and tissues isolated 3 h later. Representative examples of Western blots of rat protein lysates isolated from (A) rat PBMCs,
(B) Hippocampus, or (C) Cortex, are provided using the antibodies stated. In (A), we also provide a comparison of vehicle treated rat PBMC lysate with rat brain
cortex lysate with every antibody as evidence for the utility of each antibody (antibody control). The ratio of expression of GSK3 phosphorylation at the N-terminal
inhibitory site to the overall isoform expression was quantified from the images as detailed in section “Materials and Methods,” and is provided for each tissue (±SD)
in the table inserted into A. The red box highlights the major biomarker changes in response to lithium, although only the P-GSK3β-total GSK3β ratio was
significantly increased by lithium (p < 0.05, student t test).
not significantly different (p > 0.05), implying that development
of MCI does not alter this aspect of GSK3 regulation, at least
in PBMCs. Similarly, an IP assay of GSK3 activity indicated a
possible trend of increased GSK3β activity in the MCI group,
however, this did not reach significance (Figure 4C). The GSK3
substrate, c-myc, was detected in human PBMCs (Figure 4B),
however, there was not a significant difference in the c-myc:actin
ratio between controls and MCI (0.143 ± 0.1 controls, vs.
0.129 ± 0.1 MCI, p = 0.77). This protein is degraded upon
phosphorylation by GSK3, hence the data would suggest no
significant increase in GSK3 activity in MCI PBMCs.
Does Lithium Affect GSK3 Biomarkers
in Human PBMCs
Although the GSK3 biomarkers were not significantly altered
in PBMCs in people with MCI we proposed that they could
still be of use to monitor GSK3 activity status in response
to interventions which work through modulating GSK3, such
as lithium. Therefore, we performed study Arm 2 generating
up to eight different PBMC preparations from each of the 11
volunteers, taken at various stages during a step wise increasing
lithium dosing schedule (Figure 1). Separate blood samples were
TABLE 4 | GSK3 specific activity (measured by IP assay) in rat tissue lysates.
2 mmoles 4 mmoles All LiCl
Vehicle LiCl LiCl samples
PBMC
GSK3a 2736 ± 752 3250 ± 805 3660 ± 736 3455 ± 798
GSK3b 9703 ± 640 8130 ± 611∗ 8997 ± 895 8563 ± 880∗
Hippocampus
GSK3a 19497 ± 2077 17953 ± 984 19681 ± 2140 18817 ± 1877
GSK3b 15029 ± 1296 15135 ± 2689 14729 ± 1598 14932 ± 2221
Cortex
GSK3a 21260 ± 3052 20553 ± 5438 17391 ± 4674 18972 ± 5311
GSK3b 14554 ± 940 16175 ± 1262 14577 ± 2593 15376 ± 2190
CPM/100 µg of tissue protein lysate ± SD, n = 4, ∗p < 0.05 vs. vehicle.
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TABLE 5 | Expression of potential biomarkers of GSK3 function in rat tissues.
Expression Expression in Expression Response to
Biomarker in PBMCs Hippocampus in Cortex lithium injection
Total GSK3α
and β protein
+++ +++ +++ No
P-SER9/21
GSK3





No No No ---------
P-TYR GSK3 + +++ +++ No
GSK3α activity ++ ++++ +++ No
GSK3β activity +++ +++ +++ Yes, but not dose
dependent and in
PBMCs only.
B-catenin − +++ −
P-509CRMP2 − ++ ++ No
P-509CRMP4 − +++ +++ No
P-B-CATENIN − + − No
VASP ++ + + No
P-glycogen
synthase
++ − − No
PTAU231 − +++ ++ No
PTAU396 − ++ + No
TAU5 − ++
P-ERK + +++ +++
P-PKB473 + +++ +++ No
P-PKB308 − − − ---------
Ribosomal S6 − ++ +++ No
Phospho-S6 + ++ +++ No
+, ++, +++ represents increasing levels of detection, – represents very weak and
inconsistent detection.
TABLE 6 | Rat plasma lithium levels achieved after a single i.p. dose of lithium
chloride.
Rat Lithium
number dose Plasma lithium (mmoles/l) Averages
1 Vehicle(NaCl) Not detectable (0.15 detection limit)
4 Vehicle Not detectable Not detectable
7 Vehicle Not detectable
10 Vehicle 0.17
5 2 mmoles/kg 0.39
2 ‘’ 0.83
11 ‘’ 0.87 0.83 mM
8 ‘’ 1.23
6 4 mmoles/kg 0.94
9 ‘’ 1.02
3 ‘’ 1.78 1.635 mM
12 ‘’ 2.8
taken at every time point to measure plasma lithium and isolate
PBMC preparations, respectively, and so biomarker detection
in the PBMC preparations could be linked to changes in blood
lithium (Table 3). Two volunteers withdrew while on low dose
(ID 19 and 24), two on medium dose (ID 21 and 32), one
did not take the lithium (ID 20) and one failed to attend on
more than one occasion. This left five volunteers who completed
the full 8 sample set (Figures 1, 2). Low dose lithium did not
generate detectable plasma lithium levels (Table 3), medium dose
raised plasma lithium to detectable levels in only four out of the
eight volunteers that remained at this stage, with 0.45 mmol/l
the highest reported level on medium dose (ID 32). Finally,
high dose treatment raised plasma levels in every volunteer (ID
29,15,14,16,10, and 30), with an average of 0.415 mmol/l and a
range of 0.33–0.61 in these six volunteers (Table 3). All lithium
levels returned to baseline within 3 weeks of discontinuation.
Five volunteers (ID 10, 14, 15, 16, and 30) provided all eight
PBMC preparations (baseline, six samples during dosing and a
final washout sample, Figure 1). The PBMC preparations had
significant variation in the quality of protein recovery, even
across the samples isolated from the same individual (Figure 5A),
however, this was not related to the lithium dose at time of
blood collection. We examined the expression of the GSK3
biomarkers detectable in rat and human PBMCs, across these
eight samples for each of the five volunteers. Quantitation of
these immunoblots was problematic due to the high variability
in loading controls (despite matching loading for total protein),
which implies protein degradation or dephosphorylation in many
of the samples. Indeed, it is worth noting that the variability and
quality of the P-GSK3 and P-PKB signals in Figure 5B were very
sensitive to even minor variations in protein (Figure 5A) and
housekeeping protein (Figure 5B, actin). For example compare
protein, b-actin, P-GSK3 and P-PKB in volunteer D15, visit 2,
3, and 4 (protein and b-actin degradation) with volunteer D14,
visit 6, 7, and 8. Therefore, although we found no significant
effect of lithium on the phosphorylation of GSK3 and PKB
(Figure 5B and quantified in Supplementary Table), or the
activity of either GSK3 isoform (GSK3 beta activity shown in
Figure 5C, p > 0.05), the extensive variation in human PBMCs
may have greatly reduced the power to detect effect sizes of those
seen in the rat study. It should be noted that the highest blood
lithium levels (visits 6 and 7 in Figure 5) never reached the
lithium levels in the acute dosing rat study, and this implies that
0.33–0.61 mM plasma lithium is not sufficient to regulate the
inhibitory phosphorylation of GSK3β in human PBMCs.
These data emphasize the need to improve the standard PBMC
isolation process, identify further GSK3 activity biomarkers, and
increase volunteer numbers to utilize PBMC preparations for
monitoring GSK3 activity.
DISCUSSION
This was a preliminary study to investigate the feasibility and
methodology around performing GSK3 functional biomarker
development in a highly relevant human population. The study
had several research goals, firstly to validate which of the
numerous potential biomarkers of GSK3 biology could be
detected in PBMCs, secondly to establish whether expression of
these detectable biomarkers was affected by a diagnosis of MCI,
thirdly, to investigate whether expression of these biomarkers
was modified by treatment with lithium, at a dose up to that
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FIGURE 4 | Comparison of Biomarkers of GSK3 in human PBMCs isolated from volunteers with MCI and controls (Study Arm 1). Protein lysates were prepared from
PBMCs isolated from two groups of human volunteers, one with a diagnosis of MCI, the other age matched but with no MCI. In each case the volunteer provided
two blood samples for PBMC preparation, taken 12 weeks apart (Visit 1 and 2). (A) Representative Coomassie protein staining of PBMC lysates from 8 of the 17
volunteers in Study Arm 1, where equal total protein was loaded on the gel. (B) Representative immunoblots of biomarkers within the PBMCs of four of the
volunteers in Study arm 1. (C) Immunoprecipitation and assay of GSK3 isoforms from 50 µg of protein lysate in each of the PBMC samples. The specific activity was
quantified for GSK3alpha and GSK3beta from all PBMC preparations and the average activity (±SE) for the MCI and control groups at each visit, as well as the two
visits combined, is given.
used to treat Bipolar disorder, and finally to add to the growing
information on tolerance of lithium in the MCI population.
The hope was that we would generate information to inform
the design of a larger clinical assessment of lithium treatment
for the prevention of progression from MCI to dementia
(Sutherland and Duthie, 2015). Validated biomarkers of GSK3
function in human PBMCs could have potential use in multiple
other conditions, including diabetes, inflammation, and cancer
(Wagman et al., 2004; Hernandez et al., 2009; Castillo-Quan et al.,
2016; Jope et al., 2017; Robertson et al., 2018). GSK3 inhibition
is considered to have potential therapeutic value in all of these
conditions, therefore robust, easily attainable markers of GSK3
may have clinical utility in diagnosis, prognosis and response to
therapy (such as response to lithium).
Although there are a host of potential biomarkers for GSK3
function in cells and tissues, none are, in themselves, ideal for
accurate and complete assessment of GSK3 activity. The main
biomarker used in numerous studies is the phosphorylation
status of Ser21 of GSK3α, and the equivalent residue Ser9
in GSK3β (Hye et al., 2005; Li et al., 2007; Soutar et al.,
2010). However, while this modification is associated with
GSK3 activity (Sutherland et al., 1993) it is a semi-quantitative,
comparative measure and only assesses GSK3 activity toward
primed substrates (Frame et al., 2001), which may not represent
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all of the clinically relevant GSK3 substrates (e.g., tau).
Importantly, it does not reflect GSK3 regulation by other
mechanisms, including by small molecule inhibition. Although
some small molecule inhibitors such as lithium do enhance
this phosphorylation it is unlikely to be as potent an inhibitory
mechanism as direct inhibition through the active site of GSK3,
and the two mechanisms may function at distinct lithium
concentrations. Therefore, monitoring this phosphorylation site
provides incomplete information on overall GSK3 regulation and
function. Additional approaches include measuring upstream
regulatory pathways, such as the PI3K-Akt pathway which
regulates cellular GSK3 in response to insulin and some growth
factors. However, other pathways including the Ras-MAPK,
PKA and mTOR-S6K can complicate the input of the PI3K-
PKB regulation (Eldar-Finkelman et al., 1995), and the degree
of upstream pathway activation does not necessarily reflect
the degree of GSK3 inhibition. Therefore, we believe that
the most accurate approach is to combine assessment of the
Ser21/9 phosphorylation status, the inherent activity of GSK3
isoforms (by IP assay), while simultaneously measuring the
phosphorylation of a range of substrates known to be directly
targeted by GSK3. This would provide a more quantitative and
complete assessment of GSK3 functional status. Indeed, many of
the targets of GSK3 become targets for the β-TrCP ubiquitination
system, thereby directing them to the proteasome for destruction
(Robertson et al., 2018). Therefore, there may be a panel of
GSK3 targets whose protein levels provide a functional measure
of GSK3 activity steady state level. What is clear is that in order
to develop accurate tools to monitor GSK3 activity in clinical
trials we need validated, selective and sensitive biomarkers of
GSK3, either in tissues of importance to disease or in surrogate
tissues (such as blood cells). This was the starting point for
our investigation of the range of potential biomarkers of GSK3
function listed in Table 1.
Limitations of the Current Study
Unfortunately, our study failed to achieve the desired outcome
of establishing a panel of biomarkers for GSK3 that could be
used to track early disease or drug response, and determine
the appropriate dose of lithium for inhibiting GSK3 in MCI
volunteers. This was mainly due to the unexpected poor
quality of biomarker detection from PBMCs, which meant
our studies were underpowered. However, we established
a number of methodological issues and the data does
question the clinical utility of most of the biomarkers listed
in Table 1. Firstly, very few of them were detectable (by
immunoblot) in PBMCs in rats or humans. Secondly, and
probably most importantly, the quality and reproducibility
of the signaling proteins (especially phosphoproteins)
isolated from human PBMCs using standard protocols was
disappointingly poor. Finally, our study in the rats indicated
that there may be a complex non-linear relationship between
plasma lithium level, GSK3 regulation in PBMCs and GSK3
regulation in brain.
Most of the biomarkers from Table 1 are only readily
detectable in tissues where their function is important, (e.g.,
glycogen synthase is most highly expressed in muscle or liver
FIGURE 5 | Continued
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FIGURE 5 | Comparison of Biomarkers of GSK3 in human PBMCs isolated from volunteers with MCI treated with a stepwise increasing dose of Lithium (Study Arm
2). Protein lysates were prepared from PBMCs isolated from volunteers with MCI who underwent lithium treatment (see Figure 1). (A) Protein profiles (Coomassie
staining) from the PBMC lysates of the five volunteers that completed eight visits. Equal amounts of protein were loaded in each lane (by Bradford assay).
(B) Immunoblot of all of the lysates from the same five volunteers using the phosphoser9/21 GSK3 antibody. The box around visit 6 and 7 highlights the samples
with the peak plasma lithium levels (Table 3). (C) GSK3β isoform specific activity in PBMCs isolated across the eight visits for four of the five volunteers that
completed the study. The average GSK3β activity for each visit and the average GSK3β activity relative to the baseline activity for each volunteer are given under the
graph. The box highlights samples (6 and 7) with the peak plasma lithium levels (Table 3).
tissues, while tau is neuronally enriched), and as such it is perhaps
not surprising that many are not highly expressed in blood cells.
The list of potential “GSK3 biomarkers” is actually much greater
than that listed in Table 1, with more than 100 substrates of
GSK3 reported in the literature (Sutherland, 2011). However,
those in Table 1 are the best validated targets, and/or those with
the most sensitive and specific antibodies, to facilitate detection
by immunoblotting. We propose that it is now time to widen the
search for well validated GSK3 targets to aid the development
of a “GSK3 biomarker panel” for application to multiple tissues
and species (Robertson et al., 2018), and it may be sensible to
move to quantitative proteomic technology rather than relying
on immunoblotting.
We would also propose that improved protocols to isolate
human PBMCs (or other blood cells) are required to permit
quantification of metabolic signaling pathways. Molecules such
as GSK3 are regulated by a wide variety of extracellular cues.
This may include some of the chemicals involved in PBMC
isolation, or volunteer specific characteristics such as hormonal
or diurnal cycles and dietary or stress influences on the day of
blood collection. Indeed, the high degree of variation in our
human PBMC preparations compared to the rat preparations
would point to these latter influences as worthy of consideration.
Previously, increased GSK3 protein levels were found in
white blood cells in AD and MCI patients (Hye et al., 2005),
while reduced GSK3 phosphorylation was found in platelets
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of MCI patients (Forlenza et al., 2011b). We were not able
to confirm these important findings possibly due to the poor
quality of our PBMC protein preparations. It is also worth
noting that the relationship between plasma lithium and GSK3β
phosphorylation and activity in rat PBMCs was unusual. There
was a similar effect on GSK3 inhibition at 0.83 and 1.6 mM
plasma lithium. This may mean that the maximal dose dependent
effect on GSK3β phosphorylation was below 0.83 mM, however,
the degree of effect on GSK3 was not major (<twofold
enhancement of phosphorylation and around 15% inhibition).
This may be related to the fact we examined a single time point
or the nature of this biomarker (phosphorylation rather than
direct measure of GSK3 activity). For example, if GSK3β was 50%
phosphorylated in control animals then the maximum possible
effect of lithium on phosphorylation would be a twofold increase.
As stated earlier, the IP assay is perhaps not the ideal biomarker
for effects of small molecules, as lithium would be washed away
during the IP process but it should still assess activity changes due
to the inhibitory phosphorylation. This is why we believe that the
accurate assessment of the pharmacological relationship between
plasma lithium and GSK3 regulation would be best achieved with
biomarkers that directly monitor GSK3 specific targets rather
than simply the phosphorylation of GSK3.
It was concerning that we did not detect any effects of lithium
on any GSK3 biomarkers in the brain of the rats despite achieving
relatively high plasma levels of 1.6 mM lithium (albeit acutely). In
this case we were monitoring several markers that we know are
modified by GSK3 inhibition in cell culture (Cole and Sutherland,
2008), and in animal models of GSK3 deficiency (Soutar et al.,
2010). This implies that this acute level of plasma lithium is not
sufficient to regulate GSK3 in these brain areas. Alternatively,
it is possible that either the injection resulted in a very transient
increase in plasma lithium that is not sufficient to alter these
biomarkers, or that the time point after injection was not optimal
for effects on brain biomarkers. In essence a much more extensive
study is needed to truly establish the lithium dose required to
modify GSK3 activity in these brain areas.
Despite these major technical issues around the assessment of
current GSK3 biomarkers in human PBMCs we were encouraged
by the interest of the MCI patient population, as well as the
relative safety of lithium in this population. This is consistent
with previous studies in MCI (Forlenza et al., 2011a,b) and other
conditions (Li et al., 2007; Hampel et al., 2009; Diniz et al., 2011;
McKnight et al., 2012), where lithium has been found to be more
safe and certainly manageable than current perception may have
us believe (Macdonald et al., 2008). We should also keep in mind
that lithium is a low-cost drug and even continuous monitoring
for the known side effects is relatively cheap. Therefore, we
provide further evidence that preforming an efficacy trial on the
effect of lithium on progression from MCI to dementia is not
only feasible but worthwhile. Within that study one could expand
the investigation of GSK3 biomarkers from a simple readout
for diagnosis, or drug action, to investigate any association with
conversion from MCI to dementia. As such we are actively
working to address the technical issues listed above.
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